Shire Share Discussion Threads

[romeike] 19/4/2018 16:09

Shire would never do that, it would be ridiculous! Hopefully Susan Kilby will be doing her thing.

[mbmiah] 19/4/2018 16:08

Allergan looked at shire in 2014 I think. I would take their approach more seriously than takedas tbh. I think if shires bod stipulated a ball park figure it would be very helpful, then we investors could maybe decide for ourselves whether or not to wait lol

[ny boy] 19/4/2018 16:05

I will sell all my shares for £54.88p, no less!

[steeplejack] 19/4/2018 16:03

More credible than Takeda according to some analysts interviewed on Bloomberg this afternoon

[romeike] 19/4/2018 16:02

Allergan have previously looked at Shire and have a good understanding of their business. The have the scale to make a credible bid, at least one that would be acceptable, unlike Takeda which I think could only work if combined with a spin off of NBU.

And I would happily take up to 50% Allergan paper.

[brain smiley] 19/4/2018 16:01

Allergen shares were $250 last July but now $154.Don't look like credible buyers.

[romeike] 19/4/2018 16:00

Allergan shares down 5% - this is normal - happened with AbbVie and they went on to make a cracking bid.

Shire are easily worth £58 / share and these companies know this, they are getting Shire cheap at these prices.

[steeplejack] 19/4/2018 15:59

Allergen shares are weakening simply because there is a strong likelihood that the company will issue a lot of stock to fund the acquisition.Relatively,neither Allergen or Takeda are awash with cash and a Shire acquisition will stretch their balance sheets to the limit I suspect.A third bidder could emerge of course.I'm surprised the shares aren't nearer to 42 pounds given today's news but what do I know.

[montyhedge] 19/4/2018 15:49

Allegan shareholders won't be happy.

[wynmck] 19/4/2018 15:49

allergan shares down 7.6%

[brain smiley] 19/4/2018 15:48

Allergan shares down 8%;might put Allergen off from bidding.

[soundbuy] 19/4/2018 15:41

Benchmark for Allergan - £46.50 cash (as opposed to cash/share mix) and upwards.....

[karateboy] 19/4/2018 15:41

Just came from work. What a fantastic news holders.Didn't I say some kind of leak of another bidder may have caused yesterday rise. So guys lets see other bidders joining in. £50 at least .

[broadwood] 19/4/2018 15:40

Imo Takida unlikely to go higher without offering more of their own paper and making their own situation overstretched.

[soundbuy] 19/4/2018 15:39

Clock ticking for Takeda - Allergan with time on its side.........

Interesting times

[montyhedge] 19/4/2018 15:36

Lol like it put up or shut up, problem is if they shut up, be back to £34

[broadwood] 19/4/2018 15:35

Shire noted that this was the third approach from Takeda, following a £44 proposal comprising £28 of Takeda shares and £16 per share in cash, a £45 proposal comprising £28.75 shares and £16.75 cash.

The FTSE 100 company said that it unanimously rejected the proposal, having thoroughly considered the matter with its advisers, as "it continues to significantly undervalue the company and Shire's growth prospects and pipeline".
Takeda's board stressed that it will "remain disciplined with respect to the terms of any such offer" as it wants to keep its dividend policy and investment grade credit rating.

Takeda has until 25 April to 'put up or shut up' under UK Takeover Panel rules.
Earlier this week, Shire agreed to sell its oncology business to Servier for $2.4bn in cash, representing 9.2 times 2017 revenues. Chief executive Flemming Ornskov said proceeds from the transaction will "increase optionality" and could be returned to shareholders via a buyback after the Takeda offer period concludes.
Ornskov's pay came in for criticism overnight, as he faces a busy end of month, with an annual general meeting on 24 April and first-quarter results on 26 April. Influential shareholder body Pensions & Investment Research Consultants (PIRC) said it felt the CEO's maximum potential bonus was "excessive" at 780% of his salary.

Shire shares rose more than 6% to top 4,000p for the first time since September.
Before any specific offer was confirmed, Barclays issued a sceptical note. Analysts noted that a Takeda takeover "is likely to involve a large paper element", given the "improbability" of Takeda raising the equivalent of greater than its own market cap in credit and /or equity financing for an outright takeover.
Even if the offer came at a suitably attractive price point, itself made more challenging given the recent decline in its share price, the analysts felt it would be likely to "further complicate the path to potential consummation given likely limited appeal for many investors in holding combined Takeda/Shire equity".
Even though a sizeable subgroup of Shire investors are felt likely to be happy to crystallise an exit within a reasonable valuation range, Barclays "continue to believe the offer would need to be meaningfully in excess of £40/sh to stand a reasonable chance of success".

[romeike] 19/4/2018 15:26

Allergan in formal bid process, must submit a final offer by 18th May or withdraw. Very exciting, Allergan has deeper pockets.

[ny boy] 19/4/2018 15:22

Doubt it, 2 is usually enough but I guess not rule it out, one to add on decent dips , press overnight, big move up coming I reckon towards at least 4600/4800p

[kamitora] 19/4/2018 15:22

"Following recent press speculation, Allergan confirms that it is in the early
stages of considering a possible offer for Shire plc ("Shire"). No offer has
been made. There can be no certainty an offer will be made nor as to the terms
on which any such offer would be made. A further announcement will be made
as appropriate."

[swedeee] 19/4/2018 15:20

bloody glad I held on all this way

[swedeee] 19/4/2018 15:20

must be more parties interested for the share price to increase like that

[ny boy] 19/4/2018 15:17

Will sell at 54.88p

[romeike] 19/4/2018 15:11

Presumably then Takeda released a statement today because they were getting the silent treatment from Shire as Shire was off chatting to Allergan.